Menumenu
  • Home
  • PHARMO study published in the Journal of Clinical Intensive Care and Medicine

Chemotherapy Exposure and outcomes of Chronic Lymphoid Leukemia Patients

J.G. Kuiper, et al., J Clin Invest Care Med, 2017; 2: 025-033

 

This study describes chemotherapy exposure, healthcare utilization, overall survival (OS) and progression free survival (PFS) among patients diagnosed with chronic lymphoid leukemia (CLL). Newly diagnosed CLL patients who received chemotherapy were selected from the Eindhoven Cancer Registry between 1998-2011, linked on a patient-level to the PHARMO Database Network including data on in- and out-patient drug dispensings, hospitalizations and clinical laboratory measurements. Chemotherapy was classifi ed in regimens of use based on chemotherapy combinations. OS and PFS were determined after diagnosis and after chemotherapy. Healthcare utilization was assessed in the year before diagnosis and in the year after chemotherapy. In total, 125 CLL patients received chemotherapy: 52 patients (42%) started chemotherapy within 6 months and 73 patients (58%) started chemotherapy ≥6 months after diagnosis. Mean (±SD) age was 67(±10) years and 68% was male. About 50% had one treatment line and about 25% two lines of treatment. Chlorambucil was the most common type of first line chemotherapy. Prior diagnosis, 44% were hospitalized for any cause and 94% had at least one drug dispensing. After chemotherapy, this was 43% and 98%, respectively. One-year survival rate after diagnosis was 94%. Median PFS after fi rst treatment line was 17 months for patients starting within 6 months and 27 months for patients starting ≥6 months after diagnosis. In conclusion, most CLL patients receiving chemotherapy were treated with chlorambucil. One-year after initial diagnosis, 94% were still alive. Median PFS after fi rst line chemotherapy ranged from 17 to 27 months, depending on the timing of chemotherapy

 

In order to obtain a copy of this article, please click here

Learn more about all PHARMO publications? Please click here